Skip to main content

Negotiate with time

What can actually slow aging?

What human trials, aging biomarkers and animal studies tell us about lifestyle changes and experimental therapeutics. Evidence depends on the outcome measured.

Lifestyle

Evidence for health and function is distinct from evidence that an intervention changes an aging clock.

Exercise

Strong

Evidence focus: Human mobility and physical function

The Strong rating concerns clinical function. It does not mean that every exercise program lowers every aging clock.

Physical activity has strong evidence for preserving mobility and physical function. Its effects on biological aging clocks are less consistent and depend on the program, population and measure.

Mechanism

Exercise challenges muscles and the cardiovascular system. Functional improvement and changes in blood biomarkers are different outcomes; neither should be reduced to a single biological age score.

Clock responsiveness

In the 777-person DO-HEALTH clock substudy, the home exercise program alone did not significantly change the measured clocks over three years. Omega-3 produced small effects on selected measures, and combined interventions added a PhenoAge signal. These findings do not diminish exercise's established functional benefits.

In practice

Exercise programs need to fit a person's health, abilities and recovery. No universal four-part routine or heart-rate prescription has been validated as a way to reverse aging-clock readings.

What we don't know

Which programs produce reproducible clock changes, how responses differ across populations, and whether those changes add useful information beyond strength, mobility and fitness.

Key findings

  • LIFE randomized 1,635 older adults at risk of disability; structured activity reduced major mobility disability over about 2.6 years.
  • In large studies that followed adults for several years, more active people were less likely to die during the study. This is a link, not proof that activity caused it. Active people often differ from inactive people in other ways, and people who are already unwell tend to move less.
  • The DO-HEALTH exercise intervention alone did not significantly change its measured methylation clocks.
  • A clock result is not a substitute for demonstrated improvement in function.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Diet Quality & Caloric Management

Strong

Evidence focus: Human cardiometabolic risk factors

The Strong rating concerns metabolic health evidence. Clock effects are specific to the dietary intervention and algorithm.

Dietary interventions can improve cardiometabolic risk factors. Evidence that they change aging-clock measures is more specific and does not establish longer life.

Mechanism

Nutrition and calorie intake can influence metabolic and inflammatory biomarkers. A clinical-chemistry age estimate, a methylation age estimate and a pace-of-aging measure are different outputs and may respond differently.

Clock responsiveness

CALERIE's two-year methylation analysis in 197 adults found a roughly 2–3% slowing of DunedinPACE, without significant effects on PC-PhenoAge or PC-GrimAge. DO-HEALTH found small omega-3 effects on selected clocks. These results are not evidence that every diet, fasting schedule or commercial clock behaves similarly.

In practice

The studied populations and nutritional safeguards matter. Calorie restriction or fasting is not suitable for everyone, and clock findings do not establish an individual dietary prescription.

What we don't know

How durable the clock effects are, whether they predict better clinical outcomes, and which findings generalize beyond the populations studied.

Key findings

  • CALERIE improved several cardiometabolic risk factors in adults without obesity.
  • Its clock analysis found a modest DunedinPACE effect, with no significant PC-PhenoAge or PC-GrimAge effect.
  • Months or years on an age estimate are not demonstrated added lifespan.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Smoking Cessation

Strong

Evidence focus: Human premature mortality risk

The Strong rating concerns the health benefit of stopping smoking. Methylation changes are a separate research endpoint.

Stopping smoking reduces premature mortality risk. Changes in smoking-related DNA methylation are a separate finding and do not measure complete recovery or whole-body rejuvenation.

Mechanism

Smoking leaves measurable signatures in DNA methylation. Some signatures are less pronounced in former smokers, while others persist; these associations do not establish that methylation change causes the health benefit of cessation.

Clock responsiveness

An analysis of 15,907 people found smoking-related methylation differences that attenuated after cessation, with some persistent alterations. Changes at individual smoking-associated sites are not proof that every aging clock normalizes.

In practice

The benefit of stopping smoking does not depend on buying an aging test. A clock reading cannot quantify complete recovery or replace clinical risk assessment.

What we don't know

How much specific clock changes add to standard risk assessment, and which residual methylation signals have actionable meaning for an individual.

Key findings

  • Large human studies support substantially lower premature mortality risk after cessation.
  • Many smoking-related methylation signatures attenuate, while some persist for years.
  • Improvement at selected methylation sites is not evidence of complete biological age reversal.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Sleep Optimization

Emerging

Evidence focus: Associations with aging biomarkers

The Emerging rating concerns aging-biomarker research, not the importance of treating sleep problems.

Insomnia symptoms have been associated with older epigenetic-age estimates in observational studies. This does not establish that improving sleep reverses biological aging.

Mechanism

Sleep research examines immune and metabolic pathways as well as symptoms and daytime function. Aging-marker associations cannot by themselves determine whether sleep problems cause accelerated aging or reflect other health conditions.

Clock responsiveness

A study of 2,078 older women linked insomnia symptoms mainly to an immune-related methylation age estimate. It was cross-sectional, and reported sleep duration was not associated with epigenetic age. It did not test a sleep treatment or clock reversal.

In practice

Persistent sleep problems or possible sleep apnea deserve clinical assessment. Sleep treatment should be judged by symptoms and health outcomes, rather than promised rejuvenation of a clock reading.

What we don't know

Whether treating sleep problems produces durable, reproducible clock changes, and whether any such changes predict clinical benefit.

Key findings

  • The cited clock study is observational and cannot establish causality.
  • Evidence in one population or clock does not validate effects across all clock types.
  • Treatment-driven biological age reversal remains unestablished.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Chronic Stress Reduction

Emerging

Evidence focus: Exploratory aging-biomarker research

Evidence for wellbeing should be distinguished from evidence that stress reduction slows aging.

Meditation may help with perceived stress and wellbeing. Small studies have explored aging-related biomarkers, but causal effects on epigenetic aging remain uncertain.

Mechanism

Stress-reduction research examines psychological experience and molecular changes. These outcomes are not interchangeable with reduced age-related disease or longer life.

Clock responsiveness

A small study analyzed 17 experienced meditators and 17 controls. Overall epigenetic aging did not differ between groups; exploratory associations involved age and practice history. The observational comparison does not establish treatment-driven age reversal.

In practice

Stress-management practices can be considered for wellbeing. Neither a universal meditation duration nor telomere lengthening is established as an anti-aging prescription.

What we don't know

Whether any biomarker effects are causal, reproducible and independent of other differences between participants, and whether they predict clinical benefit.

Key findings

  • Wellbeing outcomes and aging-clock outcomes require separate evidence.
  • Small observational findings do not establish randomized evidence of rejuvenation.
  • Longer life or reduced age-related disease has not been demonstrated by the cited biomarker studies.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Targeted Therapeutics

Drugs and compounds being studied for aging-related outcomes. Clinical indications, disease-specific findings and general aging benefits are different questions.

Metformin

Emerging

Evidence focus: Human aging and function outside diabetes treatment

The Emerging rating concerns investigational aging use, not metformin's established clinical indications.

Metformin is being investigated for aging-related outcomes, but benefits outside its established clinical indications remain unproven. Completed randomized trials have reported negative primary outcomes in specific populations.

Mechanism

Metformin changes glucose metabolism and cellular energy signaling. Mechanistic plausibility and effects in diabetes do not establish that it slows aging in people without diabetes.

Clock responsiveness

METFORAGING randomized 40 non-diabetic adults with treated HIV. Over 96 weeks, its primary PhenoAge result and other aging measures did not significantly differ between groups. This small, specific population does not settle effects in the general population.

In practice

Prescription treatment for defined clinical indications should be distinguished from experimental longevity use. Aging-clock findings do not establish a dose or regimen for healthy adults.

What we don't know

Whether adequately powered studies will demonstrate functional or disease benefits in people without diabetes, and how tolerability varies across populations. Trial plans are not efficacy results.

Key findings

  • METFORAGING did not demonstrate significant clock or frailty benefits in its HIV-specific population.
  • MET-PREVENT found no walking-speed benefit in frail older adults and reported tolerability concerns.
  • Observational comparisons between users and non-users cannot establish a causal longevity benefit.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Rapamycin / mTOR Inhibitors

Emerging

Evidence focus: Human aging benefit

Animal lifespan results are well replicated. The Emerging rating concerns their translation into human aging benefit.

Rapamycin has well-replicated lifespan effects in animal models. Human longevity benefits remain unproven: recent trials have not established significant methylation-clock improvement or added functional benefit alongside exercise.

Mechanism

Rapamycin inhibits mTORC1, a regulator of growth, protein synthesis and cellular recycling. Human benefit depends on how these effects balance against effects on immunity, metabolism and recovery. Other mTOR inhibitors are different treatments and their findings are not interchangeable.

Clock responsiveness

PEARL's small exploratory clock sample and RAPA-EX-01's four methylation measures showed no statistically significant between-group differences. Small samples and short follow-up limit certainty; nonsignificance is not proof of equivalent effects or absence of longer-term benefit.

In practice

Rapamycin is a prescription medication. No validated longevity regimen has been established. RAPA-EX-01 reported numerically more adverse events with sirolimus and one possibly related hospitalized pneumonia; the event-rate comparison was not statistically significant.

What we don't know

Whether any regimen produces durable human clinical benefit; whether the possible attenuation of exercise gains replicates; and how long-term safety, exposure and response vary. Biomarker activity alone cannot answer these questions.

Key findings

  • RAPA-EX-01: 40 older adults, 13 weeks; primary intention-to-treat chair-stand difference −2.13 repetitions (95% CI −4.61 to 0.34; p=.089).
  • Per-protocol sensitivity analysis favored placebo plus exercise (p=.007), suggesting possible smaller training gains with sirolimus; this was not the primary analysis.
  • Adverse-event counts were 99 versus 63; the rate difference was not statistically significant. One hospitalized pneumonia was considered possibly related.
  • PEARL analyzed 114 completers over 48 weeks. Its primary visceral-fat outcome was negative; selected female subgroup findings require replication.
  • A nine-men mechanistic study found immune-cell marker changes, without demonstrating clinical immune or longevity benefit.
  • The RTB101 phase 3 trial failed its primary respiratory-illness endpoint; earlier immune findings do not validate weekly rapamycin.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

NAD+ Precursors (NMN, NR)

Emerging

Evidence focus: Human aging-marker and condition-specific research

Raising NAD+ or changing a tissue-specific clock does not establish a general anti-aging benefit.

NAD+ precursors have exploratory human biomarker findings and some condition-specific clinical signals. Reliable evidence of general aging reversal or longer life remains lacking.

Mechanism

NR and NMN are precursors of NAD+, which participates in cellular metabolism and repair. Effects on NAD+ levels, aging estimates and clinical function are separate questions; results for NR do not automatically apply to NMN.

Clock responsiveness

A 2026 analysis reported selected muscle-clock changes in an NR cohort of 30 participants with paired muscle samples, but lacked a placebo control and applied many blood-trained clocks to muscle. A small earlier randomized NR pilot also reported exploratory clock signals. Neither establishes whole-body rejuvenation.

In practice

Supplement availability is not evidence of clinical anti-aging benefit. Findings in particular tissues or diseases do not establish a general supplementation regimen.

What we don't know

Whether reported changes replicate in controlled studies, translate into meaningful clinical outcomes, or persist over time; and whether NR and NMN have comparable effects and long-term safety.

Key findings

  • Muscle-clock responses depend on tissue and algorithm; they cannot show that NR is superior to exercise.
  • A small NR trial in mild cognitive impairment did not improve cognition.
  • A phase 2 peripheral-artery-disease trial reported a walking-distance signal, which requires confirmation and is not a general longevity result.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Senolytics (Dasatinib + Quercetin, Fisetin)

Emerging

Evidence focus: Early human disease and aging research

Findings for dasatinib plus quercetin do not establish equivalent effects for fisetin or use in healthy people.

Senolytics target senescent cells. Human trials have mixed, population-specific results: a small 2026 liver-disease trial reported a promising histology signal, without establishing rejuvenation in healthy people.

Mechanism

Senolytic research aims to remove selected senescent cells by targeting their survival pathways. Activity in an experimental model does not establish clinical benefit or a safe treatment schedule in humans.

Clock responsiveness

The recent controlled studies cited here measured liver histology or bone metabolism, not validated whole-body aging reversal. Their findings cannot establish that periodically clearing senescent cells lowers human biological age or extends life.

In practice

Dasatinib is a prescription drug; quercetin and fisetin availability as supplements does not establish the safety or efficacy of senolytic protocols. Treatment findings cannot be transferred between these compounds.

What we don't know

Whether disease-specific signals replicate, which patients benefit, and whether there is durable clinical benefit or acceptable long-term safety in healthy adults.

Key findings

  • The 2026 MASH trial randomized 31 people: fibrosis improvement without worsening MASH occurred in 8/17 versus 1/14 (p=.021).
  • The liver result is hypothesis-generating: baseline diabetes was imbalanced and a worst-case missing-data analysis was not significant.
  • Adverse events were reported by 82% versus 43% in that small trial.
  • A 60-person bone trial did not improve its primary bone-resorption endpoint; positive subgroup findings were exploratory.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)

Emerging

Evidence focus: Human aging benefit

The Emerging rating concerns aging-clock and healthy-aging claims. Semaglutide's cardiovascular and kidney benefits in high-risk trial populations are an established, separate endpoint.

Semaglutide has established trial evidence for fewer major cardiovascular events (heart attack, stroke or cardiovascular death, counted together) and kidney events in high-risk patients. In 2026 its maker reported lower protein-based organ-age estimates in trial participants, and Eli Lilly reported slower epigenetic-clock change on tirzepatide. Those clock findings are early, company-run and not yet peer reviewed.

Mechanism

These drugs mimic gut hormones that regulate appetite and insulin release. They produce large weight loss and lower blood sugar and markers of inflammation. Lower weight, better blood sugar and less inflammation each change many blood proteins, so a clock can move without aging itself changing.

Clock responsiveness

A 2026 preprint measured blood proteins in about 10,000 participants across five placebo-controlled semaglutide trials in people with overweight or obesity and cardiovascular disease or heart failure, or type 2 diabetes with kidney disease or high cardiovascular risk. Heart organ-age scores were lower on semaglutide than on placebo in all five trials, by roughly 2 to 4 years in the authors' summary, and some other organ scores were 1 to 4 years lower. Not every score improved: liver and immune scores rose early, and a June 2026 company conference poster on SELECT and two other semaglutide trials found whole-body clocks unchanged. Lilly's single-arm tirzepatide pilot found 15 epigenetic clocks advanced less than the 1.38 years elapsed in 71 people, two significantly, with no placebo group.

In practice

Semaglutide and tirzepatide are prescription medicines for obesity and type 2 diabetes. In the US, semaglutide (as Wegovy) is also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity or overweight. The clock findings do not establish an anti-aging use, a dose, or any benefit for people without these conditions.

What we don't know

Whether clock changes persist after stopping, whether they add healthy years, how they compare with equal weight loss from diet or exercise, and whether anything applies to healthy, normal-weight people. The clock analyses did not report muscle loss or other side effects, which are a recognised concern with these drugs. A US government-funded trial comparing semaglutide, other drugs and placebo in adults in their 60s was announced in 2026; enrollment is planned to start in 2027.

Key findings

  • SELECT randomized 17,604 adults with cardiovascular disease and overweight or obesity but without diabetes; semaglutide reduced major cardiovascular events (hazard ratio 0.80).
  • FLOW, in type 2 diabetes with kidney disease, reduced a kidney composite (hazard ratio 0.76) and, as a secondary outcome, deaths from any cause.
  • In the 2026 preprint, heart organ-age scores were lower on semaglutide than on placebo in all five trials. The authors say this is not proof of rejuvenation and that the clocks are not validated trial endpoints.
  • Weight loss, HbA1c and C-reactive protein did not fully account for the organ-score changes. This exploratory analysis cannot show a direct anti-aging effect.
  • Lilly's tirzepatide sub-study was single-arm and not placebo-corrected; Lilly called it preliminary and hypothesis-generating.
  • No published study has yet tested these drugs for aging outcomes in healthy, normal-weight people.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Emerging Technologies

Early research ranges from biomarker pilots to first-in-human trials. Entering a trial does not establish a safe, effective aging treatment.

Partial Cellular Reprogramming

Emerging

Evidence focus: Early human clinical translation

Entering a human trial is a research milestone, not evidence of human age reversal or established efficacy.

Partial cellular reprogramming has entered early human eye-disease testing. Initial sponsor observations are preliminary and do not establish efficacy or reversal of human aging.

Mechanism

The ER-100 study uses controlled expression of OCT4, SOX2 and KLF4 in an eye-targeted investigational treatment. Findings from a specific tissue cannot establish safe, effective whole-body reprogramming.

Clock responsiveness

Preclinical age-marker findings motivated this research, but the current human trial examines ocular safety and exploratory visual outcomes. It does not establish systemic epigenetic-age reversal.

In practice

ER-100 is being studied in a nonrandomized, open-label phase 1 trial for optic neuropathies. It is not a validated consumer anti-aging treatment.

What we don't know

Whether apparent visual changes are reproducible treatment effects, how long they last, and the longer-term risks and benefits of tissue-specific reprogramming.

Key findings

  • The registered phase 1 study plans 18 participants and focuses on safety and tolerability.
  • On 8 October 2026, the sponsor reported day-56 observations in three glaucoma participants, including visual-field changes in two.
  • Uncontrolled sponsor observations cannot establish clinical efficacy, regeneration or longer life.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Plasma Exchange & Parabiosis Research

Emerging

Evidence focus: Exploratory human plasma-exchange biomarkers

Plasma exchange, young-plasma infusion and animal parabiosis are different interventions.

A small sham-controlled human plasma-exchange study reported transient aging-clock shifts. These findings do not establish lasting health benefit or show that young donor plasma rejuvenates people.

Mechanism

Plasma exchange removes plasma and replaces it with another fluid; the cited trial used albumin, with or without intravenous immunoglobulin. It differs from transfusing young plasma or surgically joining the circulation of animals.

Clock responsiveness

The 2025 pilot enrolled 44 people, with 42 completing four small groups. Selected active-versus-sham clock comparisons favored treatment, with the strongest mean signal at intermediate sampling with immunoglobulin. The average difference versus sham was not significant at final sampling.

In practice

Plasma exchange is a medical procedure. Short-term clock changes and completer-only procedure statistics cannot establish long-term safety or a clinical anti-aging indication.

What we don't know

Whether signals persist or replicate, whether immunoglobulin or immune-cell shifts explain them, and whether they predict meaningful functional or disease outcomes.

Key findings

  • A small pilot reported transient clock changes, without established functional, cognitive or symptom benefit.
  • Significant between-group comparisons differ from the nonsignificant within-group comparisons after multiple-testing correction.
  • The corrected safety section uses a completer-only denominator; it should not support a blanket safety claim.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index

Hyperbaric Oxygen Therapy (HBOT)

Emerging

Evidence focus: Exploratory immune-cell biomarkers

The Emerging rating concerns aging-marker research, separate from HBOT's clinical use for specific medical conditions.

A small uncontrolled study reported changes in immune-cell telomeres and senescence-associated markers after hyperbaric oxygen treatment. It did not demonstrate whole-body rejuvenation, longer life or lasting clinical benefit.

Mechanism

HBOT involves breathing oxygen at increased pressure. The aging study examined selected circulating immune-cell measurements; these do not establish removal of senescent cells throughout the body.

Clock responsiveness

The 2020 study enrolled 35 adults, but telomere analyses included 25 and senescence-marker analyses 20. It lacked a control group and had short follow-up. Telomere measurements are not DNA-methylation clocks.

In practice

Use for a specific medical condition and experimental aging use require different evidence. A research course of treatment is not a validated consumer longevity protocol.

What we don't know

Whether the biomarker findings replicate under controlled conditions, how durable they are, and whether they translate into meaningful health outcomes.

Key findings

  • The principal aging study was small and uncontrolled, with smaller subsets in its biomarker analyses.
  • A senescence-associated immune marker is not proof of whole-body senescent-cell clearance.
  • Biomarker shifts do not establish rejuvenation or increased lifespan.

Sources and study context

Evidence reviewed 12 October 2026. Sources include peer-reviewed research and clearly labeled trial registries or sponsor reports. This is an editorial evidence summary, not external expert validation.

Back to index